Normal view MARC view ISBD view

In silico multi subunit vaccine design referring spike glycoprotein of SARS-COV-2 (covid–19): the world pandemic

By: Bhardwaj, A.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2021Edition: Vol.83(1), Jan-Feb.Description: 21-31p.Subject(s): PHARMACEUTICSOnline resources: Clikc here In: Indian journal of pharmaceutical sciencesSummary: Contagious human coronavirus belong to family Coronaviridae and infects human respiratory system causing the disease known as COVID-19 (World Health Organization). To eradicate the severe acute respiratory syndrome coronavirus 2 pandemic, an effective vaccine should be developed. In the current study immunoinformatics procedures were employed to introduce a novel multi-epitope subunit vaccine. This multi-epitope vaccine can activate equally class I and II human leukocyte antigen and antibody mediated immune responses. Spike glycoprotein (protein data bank Id: 6VSB) of the coronavirus was selected and analysed using immune epitope database server for prediction of potential immunogenic B and T-cell epitopes. Population conservation studies of the selected protein and predicted epitopes were also performed using population conservancy analysis tool of immune epitope database resource. The two dimensional and three dimensional structure of multi-epitope vaccine were predicted and authenticated using PROCheck and Raptor-X servers. Docking results of the multi-epitope vaccine peptide with human leukocyte antigen class I and II alleles predicted ef ficient binding and the resulted docked models were stable during simulation. In silico immune evaluation using C-ImmSim server showed that the peptide could concurrently elicit cell-mediated and humoral immune responses. Immune simulation studies significantly anticipated high levels of Immunoglobulin M and Immunoglobulin M, T-helper, T-cytotoxic cells, Interferon-γ.
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
Articles Abstract Database Articles Abstract Database School of Pharmacy
Archieval Section
Not for loan 2021-2022620
Total holds: 0

Contagious human coronavirus belong to family Coronaviridae and infects human respiratory system
causing the disease known as COVID-19 (World Health Organization). To eradicate the severe acute
respiratory syndrome coronavirus 2 pandemic, an effective vaccine should be developed. In the current
study immunoinformatics procedures were employed to introduce a novel multi-epitope subunit vaccine.
This multi-epitope vaccine can activate equally class I and II human leukocyte antigen and antibody
mediated immune responses. Spike glycoprotein (protein data bank Id: 6VSB) of the coronavirus was
selected and analysed using immune epitope database server for prediction of potential immunogenic B
and T-cell epitopes. Population conservation studies of the selected protein and predicted epitopes were
also performed using population conservancy analysis tool of immune epitope database resource. The two
dimensional and three dimensional structure of multi-epitope vaccine were predicted and authenticated
using PROCheck and Raptor-X servers. Docking results of the multi-epitope vaccine peptide with human
leukocyte antigen class I and II alleles predicted ef ficient binding and the resulted docked models were
stable during simulation. In silico immune evaluation using C-ImmSim server showed that the peptide
could concurrently elicit cell-mediated and humoral immune responses. Immune simulation studies
significantly anticipated high levels of Immunoglobulin M and Immunoglobulin M, T-helper, T-cytotoxic
cells, Interferon-γ.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer

Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.

Powered by Koha